CLRB Cellectar Biosciences Inc.

1.91
-0.04  -2%
Previous Close 1.95
Open 1.95
Price To Book 1.62
Market Cap 17,946,429
Shares 9,396,036
Volume 86,906
Short Ratio
Av. Daily Volume 115,099
Stock charts supplied by TradingView

NewsSee all news

  1. Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference

    FLORHAM PARK, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  2. Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

    FLORHAM PARK, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  3. Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

    FLORHAM PARK, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  4. Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

    Data demonstrate phospholipid ether (PLE) molecules ability to target wide range of tumors FLORHAM PARK, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) --  Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage

  5. Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

    FLORHAM PARK, N.J., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 additional data due 4Q 2019. Data at ESMO noted 33% ORR.
CLR 131
Various lymphoma
Phase 1 data September 14, 2019 noted 50% ORR.
CLR 131
Multiple myeloma
Phase 1 trial to continue to higher dose - August 14, 2019.
CLR 131 (CLOVER-2)
Solid tumors

Latest News

  1. Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference

    FLORHAM PARK, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  2. Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

    FLORHAM PARK, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  3. Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

    FLORHAM PARK, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  4. Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

    Data demonstrate phospholipid ether (PLE) molecules ability to target wide range of tumors FLORHAM PARK, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) --  Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage

  5. Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

    FLORHAM PARK, N.J., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  6. Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress

    FLORHAM PARK, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  7. Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

    FLORHAM PARK, N.J., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  8. Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    FLORHAM PARK, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  9. Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

    Data presented at the 17th International Myeloma Workshop Patients in Cohort 6 achieved a meaningful clinical benefit with a 50% overall response rate and 100% disease control FLORHAM PARK, N.J., Sept. 16, 2019

  10. Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

    FLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  11. Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

    FLORHAM PARK, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the